A Phase 1 Study to Evaluate the Safety, Tolerability, Immunogenicity and Anti-Tumour Activity of BIL06v/Alhydrogel in Patients with Advanced Solid Tumours
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 May 2018
At a glance
- Drugs BIL 06v (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- 18 May 2018 Status changed from planning to not yet recruiting.
- 14 Dec 2017 According to a Biosceptre media release. this trial is scheduled to start at three sites in Sydney Australia in 2018.
- 02 Jun 2016 New trial record